June 19 (Reuters) - QBE Insurance (QBE) :
- SEES 1H24 GROSS WRITTEN PREMIUM IS EXPECTED TO BE $13.1B
- STRATEGIC REVIEW OF NORTH AMERICA MIDDLE-MARKET
- HAS DETERMINED IT WILL COMMENCE AN ORDERLY CLOSURE OF ITS NORTH AMERICA MIDDLE-MARKET SEGMENT
- QBE HAS DETERMINED IT WILL COMMENCE AN ORDERLY CLOSURE OF ITS NORTH AMERICA MIDDLE-MARKET SEGMENT
- WILL BEGIN NON-RENEWING MIDDLE-MARKET POLICIES ACCORDING TO APPLICABLE STATE REGULATIONS, WITH GROSS WRITTEN PREMIUM EXPECTED TO BEGIN REDUCING IN FY24
- RESTRUCTURING CHARGE OF $100M BEFORE TAX WILL BE RECORDED IN THE FY24 RESULT TO ACCOUNT FOR COSTS ASSOCIATED WITH BUSINESS CLOSURE
- CONTINUES TO EXPECT FY24 GROUP CONSTANT CURRENCY GROSS WRITTEN PREMIUM GROWTH IN MID-SINGLE DIGITS
- SEES TOTAL INVESTMENT INCOME IN FIVE MONTHS TO MAY-2024 WAS $643M, WHICH IMPROVED FROM $406M IN 1Q24
(([email protected];))
- Forums
- ASX - By Stock
- QBE
- News: QBE QBE Insurance Sees 1H24 Gross Written Premium $13.1B
QBE
qbe insurance group limited
Add to My Watchlist
0.89%
!
$21.62

News: QBE QBE Insurance Sees 1H24 Gross Written Premium $13.1B
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$21.62 |
Change
0.190(0.89%) |
Mkt cap ! $32.67B |
Open | High | Low | Value | Volume |
$21.85 | $21.85 | $21.49 | $49.27M | 2.273M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 1580 | $21.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$21.62 | 1383 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 1014 | 21.650 |
26 | 6154 | 21.640 |
24 | 4747 | 21.630 |
19 | 4358 | 21.620 |
11 | 2756 | 21.610 |
Price($) | Vol. | No. |
---|---|---|
21.660 | 3900 | 30 |
21.670 | 2688 | 15 |
21.680 | 2300 | 11 |
21.690 | 2226 | 12 |
21.700 | 1621 | 7 |
Last trade - 13.05pm 22/08/2025 (20 minute delay) ? |
Featured News
QBE (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, MD & CEO
Michael Thurn
MD & CEO
SPONSORED BY The Market Online